Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). In MS, myeloid dendritic cells (mDCs) secrete elevated amounts of IL-23, a potent proinflammatory cytokine, compared to healthy donors. Here, we examined the role of CD46, a complement binding factor, in mDCs by analyzing cytokine and chemokine production in healthy donors and patients with MS. There were striking differences between these groups with increased IL-23p19, CCL3 and CCL5 production, but decreased CCL2 levels in patients. This demonstrates major differences of DC activation upon CD46 activation, with a potential role in the pathogenesis of MS.
Introduction
Multiple sclerosis is a chronic inflammatory demyelinating disease of the CNS (Hafler et al., 2005; Weiner, 2004a) in which both the release of inflammatory mediators and chemotaxis are important (Adorini, 2004; Elhofy et al., 2002) . DCs are professional antigen-presenting cells (APC) which secrete cytokines and chemokines upon maturation and play a key role in the induction of immune responses by activating naïve T cells. We previously demonstrated that mDCs from patients with MS secrete elevated amounts of IL-23 compared to healthy controls (Vaknin-Dembinsky et al., 2006) . IL-23 is a proinflammatory cytokine that consists of a specific p19 subunit associated with the shared IL-12p40 subunit (also called IL-12 beta1 subunit which associates with IL-12p35 to form IL-12 (p70)) (Frucht, 2002; Oppmann et al., 2000; Trinchieri et al., 2003) . IL-23 promotes the expansion of a specific subset of T cells secreting IL-17, a potent inflammatory cytokine (Bettelli et al., 2007) involved in several autoimmune diseases including experimental autoimmune encephalomyelitis (EAE), a murine model of MS (Komiyama et al., 2006) . Previous MS studies have also demonstrated increased amounts of IL-12p40 in the nervous system and increased IL-12 production by PBMC (Balashov et al., 1997; Comabella et al., 1998; Soldan et al., 2004) . Therefore, the production of both IL-12 and IL-23 are dysregulated in patients with MS (Gran et al., 2004) .
The engagement of CD46 at the surface of APC has been shown to modulate the production of IL-12 (p70) and/or p40 subunit, either increasing or decreasing their expression depending on the cell type and stimulus used (Karp et al., 1996; Kurita-Taniguchi et al., 2000; Schnorr et al., 1997; Smith et al., 2003) . CD46 is a widely expressed transmembrane protein initially identified as a complement regulatory protein (Seya et al., 1986) . It has then been described as a 'magnet 
